Akebia Therapeutics (NasdaqCM:AKBA) 2026 Conference Transcript

Akebia Therapeutics Conference Summary Company Overview - Company: Akebia Therapeutics (NasdaqCM:AKBA) - Focus: Improving the lives of individuals affected by kidney disease - Commercial Products: - Auryxia: A phosphate binder nearing the end of its life cycle - VAFSEO: A HIF-PHI for treating anemia in chronic kidney disease patients on dialysis, launched about a year ago [4][5] Key Points on VAFSEO - Initial Uptake: Strong initial uptake observed post-launch, but faced challenges due to the unique nature of the dialysis market [7][8] - Market Dynamics: Dialysis providers control the prescription process, affecting product availability [8] - Discontinuation Rates: Higher than expected due to initial hemoglobin dips in patients; efforts are being made to improve patient retention [10][12] - Dosing Strategy: Transitioning to a three times weekly (TIW) dosing regimen has shown promising results in reducing discontinuation rates [12][13] - Patient Access: By the end of 2025, access to approximately 275,000 patients was achieved [13] - Long-term Growth: Data supporting VAFSEO's potential to become the standard of care for anemia in dialysis patients is anticipated [14][24] Clinical Trials and Studies - VOCAL and VOICE Trials: - VOCAL: A study comparing VAFSEO to Mircera, expected to show excellent hemoglobin control [20][29] - VOICE: A randomized comparison against Epogen, with results expected early in 2027 [29][31] - Economic Perspective: Demonstrating reduced hospitalization costs could enhance the economic proposition for dialysis organizations [31] Pipeline Developments - Rare Kidney Disease Pipeline: - Praliciguat: Phase II study initiated for FSGS, targeting rapid progression to end-stage kidney disease [5][40] - AKB-097: A tissue-targeted complement inhibitor, with a basket study planned for IgAN, C3G, and lupus nephritis [40][58] - Mechanistic Rationale: Praliciguat stimulates soluble guanylate cyclase, beneficial for podocytes and anti-inflammatory [42][44] - Patient Focus: Targeting primary FSGS and genetic mutation-related FSGS while excluding secondary causes [56] Financial Position - Cash Reserves: $166 million as of Q3, with at least two years of cash runway [69] Upcoming Catalysts - Key Events: - Continued monitoring of VAFSEO's market performance - Progress on Praliciguat and AKB-097 studies - Results from VOCAL and VOICE trials expected within the next 12 months [70][72] Conclusion - Outlook: The next 12 months are anticipated to be critical for Akebia, with significant clinical readouts and potential market shifts for VAFSEO and pipeline products [72]